{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:52Z","timestamp":1793911732042,"version":"4.8.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recently approved anti-amyloid immunotherapies for Alzheimer\u2019s disease (AD) require evidence of amyloid-\u03b2 pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-\u03b2 pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-\u03b2 pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-\u03b2 pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-\u03b2 pathology can be ruled in or out without the need for PET or CSF confirmatory testing.<\/jats:p>","DOI":"10.1038\/s43587-024-00731-y","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T05:03:31Z","timestamp":1731387811000},"page":"1529-1537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4781","authenticated-orcid":false,"given":"Joseph","family":"Therriault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Lessa","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arranz Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Gonzalez-Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Vrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmet","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Hyung Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Woong","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-1570","authenticated-orcid":false,"given":"Jos\u00e9","family":"Contador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9848-3711","authenticated-orcid":false,"given":"Albert","family":"Puig Pijoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Algeciras-Schimnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-0589","authenticated-orcid":false,"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-0559","authenticated-orcid":false,"given":"Wagner","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-3833","authenticated-orcid":false,"given":"C\u00e9cile","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur C.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Fernandez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9130-5461","authenticated-orcid":false,"given":"Yi-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-2708","authenticated-orcid":false,"given":"Marcel S.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-2420","authenticated-orcid":false,"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Lu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Lukasewicz","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-1542","authenticated-orcid":false,"given":"Paolo","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-545X","authenticated-orcid":false,"given":"Sterling","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8014","authenticated-orcid":false,"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-6601","authenticated-orcid":false,"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-638X","authenticated-orcid":false,"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-569X","authenticated-orcid":false,"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-1376","authenticated-orcid":false,"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"731_CR1","doi-asserted-by":"publisher","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2212948 (2022).","DOI":"10.1056\/NEJMoa2212948"},{"key":"731_CR2","unstructured":"Lecanemab Prescribing Information (US Food and Drug Administration, 2023)."},{"key":"731_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat. Aging 3, 506\u2013519 (2023).","journal-title":"Nat. Aging"},{"key":"731_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"731_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"731_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"731_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"731_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease versus other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"731_CR9","doi-asserted-by":"publisher","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12841 (2022).","DOI":"10.1002\/alz.12841"},{"key":"731_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2022).","journal-title":"Brain"},{"key":"731_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(02)07948-5","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes, D. A. & Schulz, K. F. Uses and abuses of screening tests. Lancet 359, 881\u2013884 (2002).","journal-title":"Lancet"},{"key":"731_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM196605262742104","volume":"274","author":"TJ Vecchio","year":"1966","unstructured":"Vecchio, T. J. Predictive value of a single diagnostic test in unselected populations. N. Engl. J. Med. 274, 1171\u20131173 (1966).","journal-title":"N. Engl. J. Med."},{"key":"731_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/bmj.329.7459.209","volume":"329","author":"D Pewsner","year":"2004","unstructured":"Pewsner, D. et al. Ruling a diagnosis in or out with \u2018SpPIn\u2019 and \u2018SnNOut\u2019: a note of caution. Br. Med. J. 329, 209\u2013213 (2004).","journal-title":"Br. Med. J."},{"key":"731_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamainternmed.2014.1059","volume":"174","author":"AK Manrai","year":"2014","unstructured":"Manrai, A. K., Bhatia, G., Strymish, J., Kohane, I. S. & Jain, S. H. Medicine\u2019s uncomfortable relationship with math: calculating positive predictive value. JAMA Intern. Med. 174, 991\u2013993 (2014).","journal-title":"JAMA Intern. Med."},{"key":"731_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/bmj.309.6947.102","volume":"309","author":"DG Altman","year":"1994","unstructured":"Altman, D. G. & Bland, M. J. Diagnostic tests 2: predictive values. Br. Med. J. 309, 102 (1994).","journal-title":"Br. Med. J."},{"key":"731_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"731_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM197411212912106","volume":"291","author":"MA Katz","year":"1974","unstructured":"Katz, M. A. A probability graph describing the predictive value of a highly sensitive diagnostic test. N. Engl. J. Med. 291, 1115\u20131116 (1974).","journal-title":"N. Engl. J. Med."},{"key":"731_CR18","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939\u20131949 (2015).","journal-title":"JAMA"},{"key":"731_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","volume":"79","author":"WJ Jansen","year":"2022","unstructured":"Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228\u2013243 (2022).","journal-title":"JAMA Neurol."},{"key":"731_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","volume":"76","author":"CR Jack","year":"2019","unstructured":"Jack, C. R. et al. Prevalence of biologically versus clinically defined Alzheimer spectrum entities using the National Institute on Aging\u2013Alzheimer\u2019s Association research framework. JAMA Neurol. 76, 1174\u20131183 (2019).","journal-title":"JAMA Neurol."},{"key":"731_CR21","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa1909159","volume":"381","author":"C Kearon","year":"2019","unstructured":"Kearon, C. et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N. Engl. J. Med. 381, 2125\u20132134 (2019).","journal-title":"N. Engl. J. Med."},{"key":"731_CR22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM197906143002402","volume":"300","author":"GA Diamond","year":"1979","unstructured":"Diamond, G. A. & Forrester, J. S. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N. Engl. J. Med. 300, 1350\u20131358 (1979).","journal-title":"N. Engl. J. Med."},{"key":"731_CR23","doi-asserted-by":"publisher","unstructured":"Goodman, K. E., Rodman, A. M. & Morgan, D. J. Preparing physicians for the clinical algorithm era. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMp2304839 (2023).","DOI":"10.1056\/NEJMp2304839"},{"key":"731_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ana.21706","volume":"66","author":"JA Schneider","year":"2009","unstructured":"Schneider, J. A., Arvanitakis, Z., Leurgans, S. E. & Bennett, D. A. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200\u2013208 (2009).","journal-title":"Ann. Neurol."},{"key":"731_CR25","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","volume":"96","author":"J Therriault","year":"2021","unstructured":"Therriault, J. et al. Frequency of biologically-defined AD in relation to age, sex, APOE\u03b54 and cognitive impairment. Neurology 96, e975\u2013e985 (2021).","journal-title":"Neurology"},{"key":"731_CR26","doi-asserted-by":"crossref","unstructured":"The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N. Engl. J. Med. 379, 1403\u20131415 (2018).","DOI":"10.1056\/NEJMoa1800474"},{"key":"731_CR27","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1056\/NEJMoa1803377","volume":"380","author":"JT Neumann","year":"2019","unstructured":"Neumann, J. T. et al. Application of high-sensitivity troponin in suspected myocardial infarction. N. Engl. J. Med. 380, 2529\u20132540 (2019).","journal-title":"N. Engl. J. Med."},{"key":"731_CR28","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"731_CR29","doi-asserted-by":"publisher","unstructured":"Therriault, J. et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13026 (2023).","DOI":"10.1002\/alz.13026"},{"key":"731_CR30","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41467-024-46603-2","volume":"15","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings. Nat. Commun. 15, 2311 (2024).","journal-title":"Nat. Commun."},{"key":"731_CR31","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. eBioMedicine 102, 105046 (2024).","journal-title":"eBioMedicine"},{"key":"731_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"2024","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for Alzheimer\u2019s disease comparable or superior to clinical CSF tests. Nat. Med. 2024, 1085\u20131095 (2024).","journal-title":"Nat. Med."},{"key":"731_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.4485","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid-PET versus with tau-PET. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485 (2022).","journal-title":"JAMA Neurol."},{"key":"731_CR34","doi-asserted-by":"publisher","first-page":"e17123","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e17123 (2023).","journal-title":"EMBO Mol. Med."},{"key":"731_CR35","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton, N. J. et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat. Med. 28, 2555\u20132562 (2022).","journal-title":"Nat. Med."},{"key":"731_CR36","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver, B. et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 29, 1775\u20131781 (2023).","journal-title":"Nat. Med."},{"key":"731_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s43587-023-00565-0","volume":"4","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat. Aging 4, 247\u2013260 (2024).","journal-title":"Nat. Aging"},{"key":"731_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak, A. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 18, 158\u2013172 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"731_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller, C. et al. Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 91, 263\u2013270 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"731_CR40","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(18)30231-X","volume":"17","author":"JJ Bazarian","year":"2018","unstructured":"Bazarian, J. J. et al. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 17, 782\u2013789 (2018).","journal-title":"Lancet Neurol."},{"key":"731_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287\u2013297 (2023).","journal-title":"JAMA Neurol."},{"key":"731_CR42","doi-asserted-by":"publisher","first-page":"E1299","DOI":"10.1212\/WNL.0000000000008160","volume":"93","author":"M Watanabe","year":"2019","unstructured":"Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93, E1299\u2013E1311 (2019).","journal-title":"Neurology"},{"key":"731_CR43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"731_CR44","doi-asserted-by":"crossref","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","DOI":"10.1038\/s41467-021-23620-z"},{"key":"731_CR45","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.34","author":"JL Cummings","year":"2023","unstructured":"Cummings, J. L. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. https:\/\/doi.org\/10.14283\/jpad.2023.34 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"731_CR46","first-page":"398","volume":"8","author":"JL Cummings","year":"2021","unstructured":"Cummings, J. L. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheimers Dis. 8, 398\u2013410 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"731_CR47","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain 139, 1551\u20131567 (2016).","journal-title":"Brain"},{"key":"731_CR48","doi-asserted-by":"publisher","first-page":"eabc8693","DOI":"10.1126\/scitranslmed.abc8693","volume":"14","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer\u2019s disease. Sci. Transl. Med. 14, eabc8693 (2022).","journal-title":"Sci. Transl. Med."},{"key":"731_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-022-00204-0","author":"J Therriault","year":"2022","unstructured":"Therriault, J. et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat. Aging https:\/\/doi.org\/10.1038\/s43587-022-00204-0 (2022).","journal-title":"Nat. Aging"},{"key":"731_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodr\u00edguez","year":"2024","unstructured":"Lantero-Rodr\u00edguez, J. et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol. 147, 12 (2024).","journal-title":"Acta Neuropathol."},{"key":"731_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00405-1","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging https:\/\/doi.org\/10.1038\/s43587-023-00405-1 (2023).","journal-title":"Nat. Aging"},{"key":"731_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02443-z","author":"K Horie","year":"2023","unstructured":"Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau pathology in Alzheimer\u2019s disease. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02443-z (2023).","journal-title":"Nat. Med."},{"key":"731_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00942-2","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat. Rev. Neurol. https:\/\/doi.org\/10.1038\/s41582-024-00942-2 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"731_CR54","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 17, 1353\u20131364 (2021).","journal-title":"Alzheimers Dement."},{"key":"731_CR55","doi-asserted-by":"publisher","unstructured":"Mohs, R. C. et al. The Bio-Hermes Study: biomarker database developed to investigate blood-1 based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13722 (2024).","DOI":"10.1002\/alz.13722"},{"key":"731_CR56","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging 3, 1079\u20131090 (2023).","journal-title":"Nat. Aging"},{"key":"731_CR57","doi-asserted-by":"publisher","unstructured":"Janelidze, S., Barth\u00e9lemy, N. R., He, Y., Bateman, R. J. & Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2023.0199 (2023).","DOI":"10.1001\/jamaneurol.2023.0199"},{"key":"731_CR58","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1093\/brain\/awad196","volume":"146","author":"VK Ramanan","year":"2023","unstructured":"Ramanan, V. K. et al. Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis. Brain 146, 4508\u20134519 (2023).","journal-title":"Brain"},{"key":"731_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Accurate risk estimation of \u03b2-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimers Dement. 15, 194\u2013204 (2019).","journal-title":"Alzheimers Dement."},{"key":"731_CR60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/alz.12745","volume":"19","author":"L Beyer","year":"2023","unstructured":"Beyer, L. et al. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years. Alzheimers Dement. 19, 1020\u20131028 (2023).","journal-title":"Alzheimers Dement."},{"key":"731_CR61","doi-asserted-by":"publisher","first-page":"e8763","DOI":"10.15252\/emmm.201708763","volume":"10","author":"A Nabers","year":"2018","unstructured":"Nabers, A. et al. Amyloid blood biomarker detects Alzheimer\u2019s disease. EMBO Mol. Med. 10, e8763 (2018).","journal-title":"EMBO Mol. Med."},{"key":"731_CR62","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist, S. et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat. Med. 27, 1034\u20131042 (2021).","journal-title":"Nat. Med."},{"key":"731_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01925-w","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01925-w (2022).","journal-title":"Nat. Med."},{"key":"731_CR64","unstructured":"Campbell, M. J., Machin, D. & Walters, S. J. Medical Statistics: a Textbook for the Health Sciences (Wiley, 2021)."},{"key":"731_CR65","unstructured":"Calculator for positive predictive value (PPV) and negative predictive value (NPV) for individual tests and combined. US Food and Drug Administration https:\/\/www.fda.gov\/media\/137612\/download (2023)."}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-024-00731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-024-00731-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-024-00731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T14:05:28Z","timestamp":1731593128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-024-00731-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1038\/s43587-024-00731-y","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T. has served as a consultant for the Neurotorium educational platform, outside of the scope of the submitted work. H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program (outside submitted work). O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2\u2009years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. R.C.P. has consulted for Roche, Genentech, Eli Lilly, Eisai and Nestle, all outside the scope of the current work. M.S.-C. has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L.; has given lectures in symposia sponsored by Roche Diagnostics, S.L.U and Roche Farma, S.A.; and was granted with a project funded by Roche Diagnostics International Ltd; payments were made to the institution (BBRC). A.P.P. has served at advisory boards for Schwabe Farma Iberica. D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). S. Johnson has served at scientific advisory boards or as a consultant for ALZpath, Prothena, Roche Diagnostics, and Enigma. M.M.M. has served as a consultant and at advisory boards for Biogen, Eisai, Lilly, Merck, Roche, and Siemens Healthineers. P.R.-N. has served at scientific advisory boards and\/or as a consultant for Roche, Novo Nordisk, Eisai, and Cerveau radiopharmaceuticals. A.A.-S. has participated in advisory boards for Roche Diagnostics, Fujirebio Diagnostics and Siemens Healthineers. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}